论文部分内容阅读
目的探讨蚓激酶胶囊对糖尿病并发下肢动脉粥样硬化斑块患者的疗效。方法将58例糖尿病并发下肢动脉粥样硬化斑块的患者随机分为治疗组30例和对照组28例。对照组给予降糖、降脂、抗炎、阿司匹林抗血小板聚集等常规治疗,治疗组在常规治疗的基础上加用蚓激酶胶囊2粒口服,3次/d。2组疗程均为6周。结果治疗组有效率为96.6%,明显高于对照组的57.1%(P<0.01)。结论蚓激酶胶囊治疗糖尿病并发下肢动脉粥样硬化斑块安全有效,在降糖、降脂、抗炎及阿司匹林抗血小板聚集的基础上加服蚓激酶胶囊疗效更佳。
Objective To investigate the efficacy of lumbrokinase capsule in the treatment of patients with diabetic lower extremity atherosclerotic plaque. Methods Fifty-eight patients with diabetic lower extremity atherosclerotic plaque were randomly divided into treatment group (n = 30) and control group (n = 28). The control group was given routine therapy such as hypoglycemic, lipid-lowering, anti-inflammatory and anti-platelet aggregation of aspirin. The treatment group was given orally with 2 Lumbrokinase capsules 3 times daily on the basis of routine treatment. The two courses of treatment were 6 weeks. Results The effective rate of the treatment group was 96.6%, which was significantly higher than that of the control group (57.1%, P <0.01). Conclusion: Lumbukinase capsule is safe and effective in the treatment of diabetic lower extremity atherosclerotic plaques. It is more effective in the treatment of diabetes mellitus with anti-inflammatory drugs and anti-platelet aggregation of aspirin.